JP2019528677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528677A5 JP2019528677A5 JP2018566591A JP2018566591A JP2019528677A5 JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5 JP 2018566591 A JP2018566591 A JP 2018566591A JP 2018566591 A JP2018566591 A JP 2018566591A JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- seq
- composition
- axl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 101150022345 GAS6 gene Proteins 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1610902.7 | 2016-06-22 | ||
| GBGB1610902.7A GB201610902D0 (en) | 2016-06-22 | 2016-06-22 | Anti-Axl Antagonistic Antibodies |
| PCT/EP2017/065313 WO2017220695A1 (en) | 2016-06-22 | 2017-06-21 | Anti-axl antagonistic antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528677A JP2019528677A (ja) | 2019-10-17 |
| JP2019528677A5 true JP2019528677A5 (enExample) | 2020-07-30 |
| JP7071935B2 JP7071935B2 (ja) | 2022-05-19 |
Family
ID=56895047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566591A Active JP7071935B2 (ja) | 2016-06-22 | 2017-06-21 | 抗Ａｘｌアンタゴニスト抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11198734B2 (enExample) |
| EP (1) | EP3475305A1 (enExample) |
| JP (1) | JP7071935B2 (enExample) |
| KR (1) | KR102458196B1 (enExample) |
| CN (2) | CN116903748A (enExample) |
| AU (1) | AU2017281326A1 (enExample) |
| CA (1) | CA3025729A1 (enExample) |
| GB (1) | GB201610902D0 (enExample) |
| MX (1) | MX2018016096A (enExample) |
| WO (1) | WO2017220695A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6931609B2 (ja) * | 2014-12-18 | 2021-09-08 | ベルゲン テクノロジオーヴァーフォリング エイエス | 抗Ａｘｌアンタゴニスト抗体 |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| NL2024108B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses |
| CN115210263A (zh) * | 2020-02-28 | 2022-10-18 | 西福根有限公司 | 抗axl抗体和组合物 |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| JP2023521753A (ja) | 2020-04-08 | 2023-05-25 | ベルゲンビオ アーエスアー | 抗ウイルス療法 |
| GB202006072D0 (en) * | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| JP2024523436A (ja) * | 2021-06-16 | 2024-06-28 | 上海▲シン▼湾生物科技有限公司 | Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用 |
| WO2022269605A1 (en) * | 2021-06-24 | 2022-12-29 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| CN119968395A (zh) * | 2022-08-18 | 2025-05-09 | 百进生物科技公司 | 抗axl抗体、其抗原结合片段及其制备和使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| EP2220121B1 (en) | 2007-11-12 | 2015-08-19 | U3 Pharma GmbH | Axl antibodies |
| BRPI0820543A2 (pt) | 2007-11-15 | 2015-06-16 | Chugai Pharmaceutical Co Ltd | Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo |
| KR20120035145A (ko) | 2009-05-11 | 2012-04-13 | 우드라이 파마 게엠베하 | 인간화 ａｘｌ 항체 |
| MX2011012136A (es) * | 2009-05-15 | 2012-04-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-axl. |
| WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| WO2011159980A1 (en) | 2010-06-18 | 2011-12-22 | Genentech, Inc. | Anti-axl antibodies and methods of use |
| AU2012273955A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| WO2012175691A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| CN104955842B (zh) * | 2012-11-05 | 2018-04-10 | 皮埃尔法布雷医药公司 | 抗原结合蛋白及其作为定位产品用于治疗癌症的用途 |
| US9850297B2 (en) * | 2013-03-15 | 2017-12-26 | Amgen Inc. | Secreted frizzle-related protein 5 (SFRP5) binding proteins |
| JP2016518382A (ja) | 2013-04-26 | 2016-06-23 | ピエール、ファーブル、メディカマン | Ａｘｌ抗体薬物複合体および癌の治療のためのその使用 |
| MX380864B (es) * | 2014-01-29 | 2025-03-12 | Dana Farber Cancer Inst Inc | Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| US9986723B2 (en) | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| JP6931609B2 (ja) | 2014-12-18 | 2021-09-08 | ベルゲン テクノロジオーヴァーフォリング エイエス | 抗Ａｘｌアンタゴニスト抗体 |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| US11159088B2 (en) * | 2019-06-19 | 2021-10-26 | Appulse Power Inc. | Dual path and mode start-up circuit |
| GB202004189D0 (en) * | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
-
2016
- 2016-06-22 GB GBGB1610902.7A patent/GB201610902D0/en not_active Ceased
-
2017
- 2017-06-21 CA CA3025729A patent/CA3025729A1/en active Pending
- 2017-06-21 CN CN202310799984.3A patent/CN116903748A/zh active Pending
- 2017-06-21 JP JP2018566591A patent/JP7071935B2/ja active Active
- 2017-06-21 EP EP17732875.4A patent/EP3475305A1/en not_active Withdrawn
- 2017-06-21 CN CN201780038590.9A patent/CN109311997B/zh not_active Expired - Fee Related
- 2017-06-21 AU AU2017281326A patent/AU2017281326A1/en not_active Abandoned
- 2017-06-21 WO PCT/EP2017/065313 patent/WO2017220695A1/en not_active Ceased
- 2017-06-21 MX MX2018016096A patent/MX2018016096A/es unknown
- 2017-06-21 US US16/098,933 patent/US11198734B2/en active Active
- 2017-06-21 KR KR1020187036968A patent/KR102458196B1/ko active Active
-
2021
- 2021-11-02 US US17/516,916 patent/US11732048B2/en active Active
-
2023
- 2023-06-29 US US18/216,085 patent/US20240190972A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528677A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| HRP20241381T1 (hr) | Nova anti-pd-1 protutijela | |
| NZ752294A (en) | Cd3 binding antibodies | |
| JP2019107018A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2017514461A5 (enExample) | ||
| JP2012254092A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| JP2017176174A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| JP2016536342A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2018536393A5 (enExample) |